文献速递肿瘤 PET/CT放射性药物与辐射防护

nanoScan PET/CT与PET/MR对18F和89Zr定量成像与离体生物分布的比较

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice.
PubMed 文献 · EJNMMI Res · 2021-06-12

该研究在N87肿瘤小鼠模型中比较了临床前PET/CT和PET/MR与离体γ计数生物分布对18F和89Zr标记示踪剂的定量性能。结果显示肿瘤摄取两种方法一致性较好,平均PET/离体比值0.8-0.9,偏差不超过10%;但健康器官如脑、肾和肝的定量一致性较差,且取决于器官和放射性核素。

要点

  • 肿瘤对18F和89Zr标记示踪剂的PET定量与离体生物分布一致性较好。
  • 健康器官(脑、肾、肝)的PET与离体定量一致性较差,取决于器官和核素。
  • 体模中18F的恢复系数最高,68Ga最低。

核心结论

  • 临床前PET对18F和89Zr标记示踪剂的肿瘤摄取定量可靠,可作为离体生物分布的有价值替代方法。
  • PET与离体定量需要完整描述实验和分析流程以确保可靠性和可重复性。

研究设计与样本

  • 研究使用NEMA NU 4-2008体模填充11C、68Ga、18F或89Zr溶液,在Mediso nanoPET/CT和PET/MR扫描仪中扫描至衰变。
  • N87肿瘤荷瘤小鼠静脉注射[18F]FDG约14 MBq后麻醉50分钟成像20分钟,或注射[89Zr]Zr-DFO-NCS-trastuzumab约5 MBq后3天成像45分钟。
  • PET采集后处死动物,收集感兴趣器官并用γ计数器测量示踪剂摄取水平。
  • PET数据使用TeraTomo重建算法进行衰减和散射校正,感兴趣区用Vivoquant软件绘制。
  • PET成像与离体生物分布使用Bland-Altman图比较。

主要发现

  • 体模中18F在PET/CT和PET/MR中恢复系数最高,即部分容积效应最小。
  • 11C和89Zr的恢复系数略低,68Ga在两种扫描仪中恢复系数最低。
  • 体内肿瘤对18F或89Zr标记示踪剂的摄取,无论用PET/CT、PET/MR还是离体生物分布定量,结果相似,平均PET/离体比值0.8-0.9,偏差不超过10%。
  • 健康器官如脑、肾和肝的示踪剂摄取定量一致性较差,取决于所评估器官和所用放射性核素。

临床怎么用

  • 在临床前肿瘤模型中,可用PET定量替代离体生物分布评估18F和89Zr标记示踪剂的肿瘤摄取。
  • 对健康器官的定量需谨慎解读,因PET与离体方法一致性较差且依赖器官和核素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The assessment of ex vivo biodistribution is the preferred method for quantification of radiotracers biodistribution in preclinical models, but is not in line with current ethics on animal research. PET imaging allows for noninvasive longitudinal evaluation of tracer distribution in the same animals, but systemic comparison with ex vivo biodistribution is lacking. Our aim was to evaluate the potential of preclinical PET imaging for accurate tracer quantification, especially in tumor models. METHODS: NEMA NU 4-2008 phantoms were filled with 11C, 68Ga, 18F, or 89Zr solutions and scanned in Mediso nanoPET/CT and PET/MR scanners until decay. N87 tumor-bearing mice were i.v. injected with either [18F]FDG (~ 14 MBq), kept 50 min under anesthesia followed by imaging for 20 min, or with [89Zr]Zr-DFO-NCS-trastuzumab (~ 5 MBq) and imaged 3 days post-injection for 45 min. After PET acquisition, animals were killed and organs of interest were collected and measured in a γ-counter to determine tracer uptake levels. PET data were reconstructed using TeraTomo reconstruction algorithm with attenuation and scatter correction and regions of interest were drawn using Vivoquant software. PET imaging and ex vivo biodistribution were compared using Bland-Altman plots. RESULTS: In phantoms, the highest recovery coefficient, thus the smallest partial volume effect, was obtained with 18F for both PET/CT and PET/MR. Recovery was slightly lower for 11C and 89Zr, while the lowest recovery was obtained with 68Ga in both scanners. In vivo, tumor uptake of the 18F- or 89Zr-labeled tracer proved to be similar irrespective whether quantified by either PET/CT and PET/MR or ex vivo biodistribution with average PET/ex vivo ratios of 0.8-0.9 and a deviation of 10% or less. Both methods appeared less congruent in the quantification of tracer uptake in healthy organs such as brain, kidney, and liver, and depended on the organ evaluated and the radionuclide used. CONCLUSIONS: Our study suggests that PET quantification of 18F- and 89Zr-labeled tracers is reliable for the evaluation of tumor uptake in preclinical models and a valuable alternative technique for ex vivo biodistribution. However, PET and ex vivo quantification require fully described experimental and analytical procedures for reliability and reproducibility.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chomet M, Schreurs M, Vos R, et al. Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice. EJNMMI Res. 2021. PMID: 34117946. doi:10.1186/s13550-021-00799-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。